Any mutagenesis assay aimed at elucidating the factors leading to an increased incidence of cancer and purporting to play a relevant role in cancer risk assessment should preferably be applicable to several species, i.e. mouse, rat and human. The existence of a cellular pathway with gene(s) that have been evolutionarily conserved from nematodes to man provide the potential to determine mutant frequencies in virtually any organ of any vertebrate species. All parts for the development of an eukaryotic mutagenesis assay based on an evolutionary conserved, expressed gene are readily available and have been characterized in some detail. Such an assay would be of great value to human cancer risk assessment and the extrapolation of mutagenicity data between species. It is anticipated that the successful development of this new in vivo model will provide a unique opportunity to study in vivo mutant frequencies in human tissues and cell lines established from human tissues.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
5R43CA093242-02
Application #
6475799
Study Section
Special Emphasis Panel (ZCA1-SRRB-U (M2))
Program Officer
Arya, Suresh
Project Start
2001-08-01
Project End
2004-01-31
Budget Start
2002-08-01
Budget End
2004-01-31
Support Year
2
Fiscal Year
2002
Total Cost
$193,291
Indirect Cost
Name
Leven, Inc.
Department
Type
DUNS #
City
Bogart
State
GA
Country
United States
Zip Code
30622